Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Onglyza Data From Sentinel Pilot Can Be Validated By Phase IV Trial, FDA Says

Executive Summary

Bristol-Myers Squibb/AstraZeneca’s type 2 diabetes treatment Onglyza (saxagliptin) has been chosen as the focus of the first drug evaluation in the mini-Sentinel active safety surveillance project in part because observational findings on the drug can be compared to a large Phase IV clinical trial now under way.
Advertisement

Related Content

Mini-Sentinel Expanding Drug Safety Efforts To Prospective Surveillance
Mini-Sentinel Project Will Evaluate Impact Of LABA Label Change
Mini-Sentinel Project Will Evaluate Impact Of LABA Label Change
EHRs A Vehicle For Delivering REMS Data To Physicians – FDA’s Woodcock
EHRs A Vehicle For Delivering REMS Data To Physicians – FDA’s Woodcock
PDUFA V: Sentinel, Regulatory Science Upgrades Could Gain User Fee Funding
Sentinel Research, Communication Transparency Needed, GSK’s Troy Urges
Sentinel Pilot Begins Scanning Drug Data, But Device Work Still Exploratory
"Mini Sentinel" With Harvard Gets FDA Halfway To Health Record Target
"Mini Sentinel" With Harvard Gets FDA Halfway To Health Record Target

Topics

Advertisement
UsernamePublicRestriction

Register

PS053041

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel